STUDY SPACE
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis

Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis

2024-03 | Nail Benallegue, MD, PhD; Fabien Rollot, MSc; Sandrine Wiertlewski, MD; Romain Casey, PhD; Marc Debouverie, MD, PhD; Anne Kerbrat, MD, PhD; Jérôme De Seze, MD, PhD; Jonathan Ciron, MD; Aurelie Ruet, MD, PhD; Pierre Labauge, MD, PhD; Elisabeth Maillart, MD; Helene Zephir, MD, PhD; Caroline Papeix, MD, PhD; Gilles Defer, MD; Christine Lebrun-Frenay, MD, PhD; Thibault Moreau, MD, PhD; Eric Berger, MD; Bruno Stankoff, MD, PhD; Pierre Clavelou, MD, PhD; Olivier Heinzel, MD; Jean Pelletier, MD, PhD; Eric Thouvenot, MD, PhD; Abdullatif Al Khedr, MD; Bertrand Bourre, MD, PhD; Olivier Case, MD; Philippe Cabre, MD, PhD; Abir Wahab, MD; Laurent Magy, MD, PhD; Sandra Vukusic, MD, PhD; David-Axel Laplaud, MD, PhD, for the OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators
A study published in JAMA Neurology analyzed the effectiveness of highly effective therapies (HETs) versus moderately effective therapies (METs) as first-line treatments for pediatric-onset multiple sclerosis (POMS). The study, conducted using data from 36 French MS centers, included 530 children with POMS who received either HET or MET before adulthood. The results showed that HETs significantly reduced the risk of the first relapse within the first 2 years, with a 54% lower risk compared to METs. HETs also led to lower MRI activity and better treatment tolerance. The risk of treatment discontinuation was six times higher with METs, primarily due to lack of efficacy and intolerance. The study suggests that HETs should be prioritized as initial treatment for POMS, although long-term safety studies are needed. The findings highlight the importance of early treatment in controlling disease activity and preventing long-term disability in children with POMS.A study published in JAMA Neurology analyzed the effectiveness of highly effective therapies (HETs) versus moderately effective therapies (METs) as first-line treatments for pediatric-onset multiple sclerosis (POMS). The study, conducted using data from 36 French MS centers, included 530 children with POMS who received either HET or MET before adulthood. The results showed that HETs significantly reduced the risk of the first relapse within the first 2 years, with a 54% lower risk compared to METs. HETs also led to lower MRI activity and better treatment tolerance. The risk of treatment discontinuation was six times higher with METs, primarily due to lack of efficacy and intolerance. The study suggests that HETs should be prioritized as initial treatment for POMS, although long-term safety studies are needed. The findings highlight the importance of early treatment in controlling disease activity and preventing long-term disability in children with POMS.
Terms of Service
Privacy Policy
Reach us at info@study.space